Astellas Pharma

top 6
Thu Bui

Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. merged to establish Astellas Pharma Inc. on April 1, 2005. The corporation announced management changes effective April 1, 2020 on February 5, 2020. Astellas is a subsidiary of the Mitsubishi UFJ Financial Group (MUFJ).

Astellas is advocating the Focus Area Approach, which focuses on Biology and Modality to discover the potential for the continued development of novel medications to address diseases with significant unmet medical needs.

Furthermore, Astellas is expanding beyond its basic Rx emphasis to develop Rx+® healthcare solutions that combine their expertise and knowledge with cutting-edge technology from external partners in other disciplines.

As a result of these initiatives, Astellas is at the vanguard of healthcare reform, transforming groundbreaking science into VALUE for patients.


Founded: 1 April 2005

Headquarters: 2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan

Key people: Naoki Okamura, Kenji Yasukawa

Website: https://www.astellas.com/en/

Screenshot of https://www.astellas.com/en/
Screenshot of https://www.astellas.com/en/
Astellas Pharma

Objective Completely Accurate

Toplist Joint Stock Company
Address: 3rd floor, Viet Tower Building, No. 01 Thai Ha Street, Trung Liet Ward, Dong Da District, Hanoi City, Vietnam
Phone: +84369132468 - Tax code: 0108747679
Social network license number 370/GP-BTTTT issued by the Ministry of Information and Communications on September 9, 2019
Privacy Policy